EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Sabra Health Care REIT Stock To Go Ex-dividend Tomorrow (SBRA)

By TheStreet Wire 05/10/12 - 08:56 AM EDT

Find out if (SBRA) is in Cramer's Portfolio.

NEW YORK (TheStreet) -- The ex-dividend date for Sabra Health Care REIT (Nasdaq:SBRA) is tomorrow, May 11, 2012. Owners of shares as of market close today will be eligible for a dividend of 33 cents per share. At a price of $15.48 as of 9:30 a.m. ET, the dividend yield is 8.4%.

The average volume for Sabra Health Care REIT has been 240,400 shares per day over the past 30 days. Sabra Health Care REIT has a market cap of $583.6 million and is part of the financial sector and real estate industry. Shares are up 28% year to date as of the close of trading on Wednesday.

Sabra Health Care REIT, Inc. operates as a real estate investment trust in the United States. The company, through its subsidiaries, owns and invests in real estate properties for the healthcare industry. The company has a P/E ratio of 31.5, below the average real estate industry P/E ratio of 36.7 and above the S&P 500 P/E ratio of 17.7.

Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Sabra Health Care REIT as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has not been very careful in the management of its balance sheet. You can view the full Sabra Health Care REIT Ratings Report.

See our dividend calendar or top-yielding stocks list.

For more information on Sabra Health Care REIT Inc. click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.